By Mae Chan
Ashwagandha is an herb from India used for centuries as a body tonic for general health of the body and mind. Adults supplemented with ashwagandha root extract had improved memory test scores, researchers in India found.
Ashwagandha has been used as an herbal remedy for hundreds of years to help the body deal with stress. It has also been used traditionally for pain relief and to treat skin diseases, diabetes, gastrointestinal disease, rheumatoid arthritis, epilepsy and many other conditions naturally.
Ashwagandha also known commonly as Indian ginseng, poison gooseberry, or winter cherry is a plant that flourishes in India and North America. The roots of the ashwagandha plant have been employed for millennia by Ayurvedic healers. Ashwagandha has many beneficial elements, including flavonoids and members of the withanolide class. Numerous modern studies have found that ashwagandha shows great promise for being effective in reducing inflammation, decreasing stress, increasing mental activity, invigorating the body, and as an antioxidant. It is even known to relieve arthritis better than medication.
Some lesser known benefits were been published in the Journal of The International Society of Sports Nutrition including improvements in muscle strength, size, and recovery.
Dietary supplements that address cognitive function are increasingly in the limelight thanks to a growing aging population, as well as the gaming, tech, and fitness culture that’s making nootropics in vogue.
Ashwagandha root has been a part of the medicinal traditions of Ayurveda as a memory aid, wrote researchers of a new study published in the Journal of Dietary Supplements. In this current study, the researchers conducted what they claimed to be the first trial that looked at “the clinical impact of ashwagandha on the cognitive deficits seen in mild cognitive impairment.”
Participants: Selecting patients of mild cognitive impairmentThe study was conducted over eight weeks using a random-assignment, parallel-group, double-blind, placebo-controlled design. Clinical visits all took place at one center, with participants being selected from different outpatient clinics in the city of Pune, India, who sought treatment for mild cognitive impairment.
To be included in the study, participants had to be aged 35 or older, have subjective symptoms of memory impairment, a previous diagnosis of early dementia or a score a certain amount in a mini-mental state examination, and the ability and willingness to provide informed consent.